It seems that the term "all other treatment options" can be a little misleading.
I just worry that a good response from this trial will have limited value as nobody will know if it was the bisantrene or the clofarabine that made the difference.
I'm assuming that part of the reason for this trial is to just get some attention for bisantrene in the clinical community.
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-32
-
- There are more pages in this discussion • 214 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |